On Thursday, officials at the Centers for Medicare and Medicaid Services announced that Medicare will limit coverage of Aduhelm, the first promising treatment for Alzheimer’s in years, to patients participating in clinical trials.
This precedent is devastating. By curtailing broad access to an FDA-approved medicine, Medicare is essentially declaring that it has the power to ration drugs.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Medicare is grabbing the power to ration approved drugs
Sally C. Pipes
On Thursday, officials at the Centers for Medicare and Medicaid Services announced that Medicare will limit coverage of Aduhelm, the first promising treatment for Alzheimer’s in years, to patients participating in clinical trials.
This precedent is devastating. By curtailing broad access to an FDA-approved medicine, Medicare is essentially declaring that it has the power to ration drugs.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.